BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 17068150)

  • 1. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.
    Yaccoby S; Ling W; Zhan F; Walker R; Barlogie B; Shaughnessy JD
    Blood; 2007 Mar; 109(5):2106-11. PubMed ID: 17068150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
    Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
    J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
    Fulciniti M; Tassone P; Hideshima T; Vallet S; Nanjappa P; Ettenberg SA; Shen Z; Patel N; Tai YT; Chauhan D; Mitsiades C; Prabhala R; Raje N; Anderson KC; Stover DR; Munshi NC
    Blood; 2009 Jul; 114(2):371-9. PubMed ID: 19417213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.
    Pennisi A; Ling W; Li X; Khan S; Wang Y; Barlogie B; Shaughnessy JD; Yaccoby S
    PLoS One; 2010 Dec; 5(12):e15233. PubMed ID: 21188144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.
    Zhou F; Meng S; Song H; Claret FX
    Blood Rev; 2013 Nov; 27(6):261-7. PubMed ID: 24054128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
    Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
    Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.
    Pozzi S; Fulciniti M; Yan H; Vallet S; Eda H; Patel K; Santo L; Cirstea D; Hideshima T; Schirtzinge L; Kuhstoss S; Anderson KC; Munshi N; Scadden D; Kronenberg HM; Raje N
    Bone; 2013 Apr; 53(2):487-96. PubMed ID: 23333523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
    Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
    Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.
    Simic MK; Mohanty ST; Xiao Y; Cheng TL; Taylor VE; Charlat O; Croucher PI; McDonald MM
    J Bone Miner Res; 2023 Jun; 38(6):814-828. PubMed ID: 36987921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice.
    Yao GQ; Wu JJ; Troiano N; Insogna K
    J Bone Miner Metab; 2011 Mar; 29(2):141-8. PubMed ID: 20602130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass.
    Morvan F; Boulukos K; Clément-Lacroix P; Roman Roman S; Suc-Royer I; Vayssière B; Ammann P; Martin P; Pinho S; Pognonec P; Mollat P; Niehrs C; Baron R; Rawadi G
    J Bone Miner Res; 2006 Jun; 21(6):934-45. PubMed ID: 16753024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model.
    Park BM; Kim EJ; Nam HJ; Zhang D; Bae CH; Kang M; Kim H; Lee W; Bogen B; Lim SK
    Yonsei Med J; 2017 May; 58(3):505-513. PubMed ID: 28332354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma.
    Feng Y; Zhang Y; Wei X; Zhang Q
    Cancer Biomark; 2019; 24(2):195-201. PubMed ID: 30614800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.
    Qian J; Zheng Y; Zheng C; Wang L; Qin H; Hong S; Li H; Lu Y; He J; Yang J; Neelapu S; Kwak LW; Hou J; Yi Q
    Blood; 2012 Jan; 119(1):161-9. PubMed ID: 22049519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.
    Li X; Ling W; Pennisi A; Wang Y; Khan S; Heidaran M; Pal A; Zhang X; He S; Zeitlin A; Abbot S; Faleck H; Hariri R; Shaughnessy JD; van Rhee F; Nair B; Barlogie B; Epstein J; Yaccoby S
    Stem Cells; 2011 Feb; 29(2):263-73. PubMed ID: 21732484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
    Yaccoby S; Wezeman MJ; Zangari M; Walker R; Cottler-Fox M; Gaddy D; Ling W; Saha R; Barlogie B; Tricot G; Epstein J
    Haematologica; 2006 Feb; 91(2):192-9. PubMed ID: 16461303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats.
    Wang FS; Ko JY; Lin CL; Wu HL; Ke HJ; Tai PJ
    Bone; 2007 Feb; 40(2):485-92. PubMed ID: 17055793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
    Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
    N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
    Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA
    Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.